OLIGOSOL Copper Gold Silver Oral solution in vial Vial/60ml

Oral solution.
Bottle of 60 mL (30 doses), with graduated cup at 2 mL (1 dose) and at 4 mL (2 doses).

For 100 mL of oral solution:

Copper gluconate: 22,50 mg
(Corresponding quantity of copper): 3,150 mg

Colloidal gold: 0,070 mg

Silver gluconate: 3,000 mg
(Corresponding quantity of silver): 1,068 mg

The cup includes two graduations corresponding to 2 mL of solution (1 dose) and to 4 mL of solution (2 doses).

Used as a constitutional modifier, particularly during the convalescence phase of infectious diseases, and in asthenic states.

Dosage

FOR ADULTS ONLY.

The contents of the cup graduations: 2 mL (1 dose) or 4 mL (2 doses).

Doses are to be taken:

• preferably in the morning on an empty stomach,
• optionally 15 minutes before a meal.

Method of administration

Oral use.

Sublingual administration is recommended: hold the contents of the cup under the tongue for 1 to 2 minutes before swallowing.

Hypersensitivity to the active substances or to any of the excipients listed in section Composition.

Very rare cases of argyria have been reported during prolonged treatment and/or overdose, see sections Adverse effects and Overdose.

The data available to date do not suggest the existence of clinically significant interactions.

In the absence of experimental and clinical data, and as a precaution, use of this medicine should be avoided during pregnancy and breastfeeding.

COPPER-GOLD-SILVER OLIGOSOL, oral solution in bottle has no effect on the ability to drive vehicles or use machines.

This medicine is generally well tolerated; the main types of adverse effects recorded since marketing are as follows:

• Gastrointestinal disorders: abdominal pain, nausea, vomiting, occasionally diarrhoea or constipation.
• Immune system disorders: rare cases of hypersensitivity reactions of the erythema or urticaria type have been reported, requiring permanent discontinuation of this medicine (frequency not determined).
• Skin and skin appendage disorders: very rare cases of argyria have been reported (frequency not determined).
• Nervous system disorders: dysgeusia (metallic taste, frequency not determined).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system: National Agency for the Safety of Medicines and Health Products (ANSM) and the network of Regional Pharmacovigilance Centres - Website: https://signalement.social-sante.gouv.fr.

Prolonged use and/or excessive doses may cause cutaneous accumulation of silver salts (argyria).

Symptoms include a slight grey or blue-grey discoloration mainly localised to the hands (particularly under the nails) or to sun-exposed areas, requiring discontinuation of treatment.

Pharmacotherapeutic class: OLIGOTHERAPY (V: various)

Trace mineral elements.

2 years.

Store below 25 °C and protected from light.

No special requirements.